Proposal to widen access to adalimumab for juvenile idiopathic arthritis and for fistulising Crohn’s disease
PHARMAC is seeking feedback on a proposal to widen access to adalimumab (Humira and HumiraPen) to include juvenile idiopathic arthritis and fistulising Crohn’s disease, and to list a 20 mg strength of Humira, from 1 July 2013, through a provisional agreement with AbbVie Limited.
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5:00 pm on Monday 29 April 2013 to:
Senior Therapeutic Group Manager
Fax: 04 460 4995
Post: PHARMAC, PO Box 10 254, Wellington 6143
All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.